

Bibliografía

- 1 New Therapeutic Strategies for Osteoarthritis by Targeting Sialic Acid Receptors
Paula Carpintero-Fernandez, Marta Varela-Eirin, Alessandra Lacetera, Raquel Gago-Fuentes, Eduardo Fonseca, Sonsoles Martin-Santamaria, Maria D. Mayan
Biomolecules. 2020 Apr; 10(4): 637. Published online 2020 Apr 21. doi: 10.3390/biom10040637
- 2 Peptide-biofunctionalization of biomaterials for osteochondral tissue regeneration in early stage osteoarthritis: challenges and opportunities. D Bicho, S Ajami, C Liu, RL Reis... - Journal of Materials ..., 2019 - pubs.rsc.org
<https://pubs.rsc.org/iv/content/articlehtml/2019/tb/c8tb03173h>
- 3 Peptide-based therapies for arthritis. Marina Ali & Nicholas Manolios/Future Rheumatol. (2007) 2(3), 287–296
Author for correspondence University of Sydney, Rheumatology Dept, Westmead Hospital, Westmead 2145, Sydney, Australia
<https://Arthodesmol.openaccessjournals.com/articles/peptidebased-therapies-for-arthritis.pdf>
- 4 Li, Q., Cong, B., Shan, B. et al. Cholecystokinin octapeptide exerts its therapeutic effects on collagen-induced arthritis by suppressing both inflammatory and Th17 responses. Rheumatol Int 31, 1291–1298 (2011).
<https://doi.org/10.1007/s00296-010-1476-4> <https://link.springer.com/article/10.1007%2Fs00296-010-1476-4>
- 5 Novel drug delivery system to bone using acidic oligopeptide: pharmacokinetic characteristics and pharmacological potential T Sekido I, N Sakura, ARTHRODESMOL Higashi, K Miya, ARTHRODESMOL Nitta, M Nomura, ARTHRODESMOL Sawanishi, K Morito, ARTHRODESMOL Masamune, S Kasugai, K Yokogawa, K Miyamoto J.Drug Target. 2001 Apr;9(2):111-21. doi: 10.3109/10611860108997922.
<https://pubmed.ncbi.nlm.nih.gov/11697106/>
- 6 RNA interference-mediated suppression of TNF- α converting enzyme as an alternative anti-TNF- α therapy for rheumatoid arthritis, Yoonsung Song, Sungsin Jo, Jee Young Chung, Younseo Oh, Subin Yoon, Young Lim Lee, Seong Su Kim, Jae-Hyuk Yang, Kiseok Jang, Chul-Su Yang, Tae-Hwan Kim, Yong-Hee Kim,; Journal of Controlled Release 2020, ISSN 0168-3659,
<https://doi.org/10.1016/j.jconrel.2020.11.041>.
- 7 Oligopeptide antagonist of IL-6: A novel approach to target IL-6 activities/October 2007/Expert Opinion on Therapeutic Patents 17(10):1309-1314/DOI: 10.1517/13543776.17.10.1309/Cem Gabay
https://Arthodesmol.researchgate.net/publication/247838224_Oligopeptide_antagonist_of_IL-6_A_novel_approach_to_target_IL-6_activities
- 8 In-Sung Yeo, Seung-Ki Min, Hyun Ki Kang, Taek-Ka Kwon, Sung Youn Jung, Byung-Moo Min, Identification of a bioactive core sequence from human laminin and its applicability to tissue engineering, Biomaterials, Volume 73, 2015, Pages 96-109, ISSN 0142-9612, <https://doi.org/10.1016/j.biomaterials.2015.09.004>.
<https://Arthodesmol.sciencedirect.com/science/article/abs/pii/S0142961215007498>
- 9 Stéphane Téletchéa, Verena Stresing, Soizic Hervouet, Marc Baud'huin, Marie-Françoise Heymann, Gildas Bertho, Céline Charrier, Kosei Ando, and Dominique Heymann. Novel RANK Antagonists for the Treatment of Bone-Resorptive Disease: Theoretical Predictions and Experimental Validation . INSERM, UMR 957, Equipe labellisée LIGUE 2012, Université de Nantes, Laboratory of the Physiopathology of Bone Resorption and Therapy of Primary Bone Tumors (LPRO), Nantes, France
<https://asbmr.onlinelibrary.wiley.com/doi/full/10.1002/jbmr.2170>
- 10 Functional site of endogenous phospholipase A2 inhibitor from python serum. Phospholipase A2 binding and anti-inflammatory activity. Maung-Maung Thwin, Ramapatna L. Satish, Steven T. F. Chan - Ponnampalam Gopalakrishnakone First published: 22 February 2002
- 11 Zhou Q, Li X, Li R, Zheng ARTHRODESMOL, Li ZG. [Proliferation of type II collagen specific T cell response and antibody formation in rheumatoid arthritis and their relations to HLA-DR4]. Zhonghua Yi Xue Za Zhi. 2005 Feb 16;85(6):370-3. Chinese. PMID: 15854524.
<https://pubmed.ncbi.nlm.nih.gov/15854524/>
- 12 <https://core.ac.uk/reader/3186734>